Y-mAbs Therapeutics price target lowered to $18 from $21 at Truist

Truist lowered the firm’s price target on Y-mAbs Therapeutics (YMAB) to $18 from $21 but keeps a Buy rating on the shares after its Q4 results and guidance. The company’s FY25 revenues are expected to be $75-$90M, which is about 30% below midpoint of consensus of $105M, and given the increased competition in the neuroblastoma space for patients, Truist is adjusting Danyelza revenues to reflect a more gradual ramp, the analyst tells investors in a research note. The firm adds however that despite the pull back in recent weeks, there is more upside for the stock and high value expected from the company’s radioimmunotherapy platform.